Abstract 407P
Background
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker to monitor molecular residual disease (MRD) in solid tumors after curative-intent treatment. Since imaging and plasma-derived protein biomarkers both have limited sensitivity and specificity, ctDNA could complement conventional methods to guide post-operative monitoring and treatment plans for patients. This study evaluated the clinical utility of our tumor-informed, personalized ctDNA assay to identify patients at high risk of recurrence.
Methods
This prospective multi-center study enrolled 510 patients with liver, colorectal, breast, lung, gastric and ovarian cancers who were eligible for curative-intent surgery. Genomic DNA extracted from tumor tissue and paired white blood cells was subjected to massively parallel sequencing of 150 cancer-related genes. A proprietary algorithm ranked the top somatic mutations unique to each patient, which were then used to detect ctDNA in serial plasma samples.
Results
The pre-operative detection rate of ctDNA was 91%, 97%, 62%, 65%, 57%, and 46% for colorectal, liver, lung, ovarian, high-risk breast cancer, and gastric cancer respectively; the specificity was >99% as ctDNA was not detected in the plasma from healthy donors. Our interim analysis after a 20-month follow-up demonstrated that 88% of patients with recurrence and/or metastasis (35/40) had ctDNA detected in their post-operative plasma samples. On average, such ctDNA detection was 5 months (up to 13 months) earlier than clinical diagnosis. Post-operative ctDNA was also found as an independent prognostic factor for disease-free survival in multiple types of cancer (p<0.001).
Conclusions
K-Track™ assay provides longitudinal ctDNA monitoring that showed clinical utility in predicting disease-free survival and early relapse detection in cancer patients. This simplified and cost-effective approach enables MRD monitoring to be more accessible in routine clinical practice in developing countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute, Ho Chi Minh City, Vietna.
Funding
Gene Solutions JSC, Ho Chi Minh city, Vietnam.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract